Literature DB >> 29920313

Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR ("Research on Adverse Drug events And Reports") program.

Kelsey A Orrell1, Morgan Murphrey1, Ryan C Kelm1, Harrison H Lee1, David R Pease1, Anne E Laumann1, Dennis P West1, Beatrice Nardone2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29920313     DOI： 10.1016/j.jaad.2018.06.024

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  6 in total

1.  Antitumor necrosis factor treatment in patients with inflammatory bowel disease does not promote psoriasis development: A meta-analysis.

Authors:  Yu Kyung Jun; Joo Young Park; Seong-Joon Koh; Hyunsun Park; Hyoun Woo Kang; Jong Pil Im; Joo Sung Kim
Journal:  Medicine (Baltimore)       Date:  2022-07-08       Impact factor: 1.817

2.  Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis.

Authors:  Steven L Truong; Jasmine Chin; David F L Liew; Syeda Farah Zahir; Elizabeth G Ryan; Diana Rubel; Graham Radford-Smith; Philip C Robinson
Journal:  Rheumatol Ther       Date:  2021-08-26

Review 3.  The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases.

Authors:  Laura Țiburcă; Marius Bembea; Dana Carmen Zaha; Alexandru Daniel Jurca; Cosmin Mihai Vesa; Ioana Adela Rațiu; Claudia Maria Jurca
Journal:  Curr Issues Mol Biol       Date:  2022-04-26       Impact factor: 2.976

4.  Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor.

Authors:  M Gooderham; B E Elewski; D M Pariser; H Sofen; A M Mendelsohn; S J Rozzo; Q Li
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-05-08       Impact factor: 6.166

Review 5.  Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors.

Authors:  Keira A Fieldhouse; Samantha Ukaibe; Erika L Crowley; Reena Khanna; Ashley O'Toole; Melinda J Gooderham
Journal:  Drugs Context       Date:  2020-04-21

Review 6.  Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis.

Authors:  Gonçalo Boleto; Matheus Vieira; Anne Claire Desbois; David Saadoun; Patrice Cacoub
Journal:  Front Med (Lausanne)       Date:  2020-11-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.